Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.39
BRKR's Cash to Debt is ranked lower than
63% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. BRKR: 1.39 )
Ranked among companies with meaningful Cash to Debt only.
BRKR' s 10-Year Cash to Debt Range
Min: 0.13  Med: 1.44 Max: N/A
Current: 1.39
Equity to Asset 0.40
BRKR's Equity to Asset is ranked lower than
77% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BRKR: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
BRKR' s 10-Year Equity to Asset Range
Min: 0.14  Med: 0.43 Max: 0.69
Current: 0.4
0.14
0.69
Interest Coverage 7.92
BRKR's Interest Coverage is ranked lower than
80% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. BRKR: 7.92 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s 10-Year Interest Coverage Range
Min: 0.71  Med: 10.91 Max: 9999.99
Current: 7.92
0.71
9999.99
F-Score: 5
Z-Score: 3.70
M-Score: -2.90
WACC vs ROIC
6.38%
8.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.75
BRKR's Operating margin (%) is ranked higher than
65% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. BRKR: 5.75 )
Ranked among companies with meaningful Operating margin (%) only.
BRKR' s 10-Year Operating margin (%) Range
Min: -3.71  Med: 6.02 Max: 13.34
Current: 5.75
-3.71
13.34
Net-margin (%) 3.13
BRKR's Net-margin (%) is ranked higher than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. BRKR: 3.13 )
Ranked among companies with meaningful Net-margin (%) only.
BRKR' s 10-Year Net-margin (%) Range
Min: -6.73  Med: 3.69 Max: 9.58
Current: 3.13
-6.73
9.58
ROE (%) 6.76
BRKR's ROE (%) is ranked higher than
68% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. BRKR: 6.76 )
Ranked among companies with meaningful ROE (%) only.
BRKR' s 10-Year ROE (%) Range
Min: -9.05  Med: 9.55 Max: 23.93
Current: 6.76
-9.05
23.93
ROA (%) 2.84
BRKR's ROA (%) is ranked higher than
65% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. BRKR: 2.84 )
Ranked among companies with meaningful ROA (%) only.
BRKR' s 10-Year ROA (%) Range
Min: -5.06  Med: 3.56 Max: 11.34
Current: 2.84
-5.06
11.34
ROC (Joel Greenblatt) (%) 18.36
BRKR's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. BRKR: 18.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BRKR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4.38  Med: 20.77 Max: 54.93
Current: 18.36
-4.38
54.93
Revenue Growth (3Y)(%) 2.50
BRKR's Revenue Growth (3Y)(%) is ranked lower than
63% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. BRKR: 2.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BRKR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 16.60 Max: 22.8
Current: 2.5
0
22.8
EBITDA Growth (3Y)(%) -5.70
BRKR's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. BRKR: -5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BRKR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 5.40 Max: 153.7
Current: -5.7
0
153.7
EPS Growth (3Y)(%) -15.70
BRKR's EPS Growth (3Y)(%) is ranked lower than
67% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. BRKR: -15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BRKR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -2.10 Max: 57.4
Current: -15.7
0
57.4
» BRKR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BRKR Guru Trades in Q3 2014

Joel Greenblatt 1,440,516 sh (+60.33%)
Murray Stahl 43,262 sh (+31.12%)
Paul Tudor Jones 32,794 sh (+18.94%)
NWQ Managers 1,312,031 sh (+8.32%)
Pioneer Investments 387,897 sh (unchged)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Louis Moore Bacon Sold Out
Jim Simons 255,960 sh (-1.22%)
» More
Q4 2014

BRKR Guru Trades in Q4 2014

Paul Tudor Jones 132,100 sh (+302.82%)
Vanguard Health Care Fund 4,669,258 sh (+42.11%)
NWQ Managers 1,698,398 sh (+29.45%)
Joel Greenblatt 1,646,395 sh (+14.29%)
Murray Stahl 43,304 sh (+0.10%)
Jim Simons Sold Out
Pioneer Investments 384,188 sh (-0.96%)
» More
Q1 2015

BRKR Guru Trades in Q1 2015

Jim Simons 226,310 sh (New)
Steven Cohen 188,200 sh (New)
Murray Stahl 45,454 sh (+4.96%)
NWQ Managers 1,700,988 sh (+0.15%)
Vanguard Health Care Fund 4,669,258 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Joel Greenblatt 903,808 sh (-45.10%)
» More
Q2 2015

BRKR Guru Trades in Q2 2015

Vanguard Health Care Fund 4,669,258 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.86
BRKR's P/E(ttm) is ranked lower than
82% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. BRKR: 64.86 )
Ranked among companies with meaningful P/E(ttm) only.
BRKR' s 10-Year P/E(ttm) Range
Min: 7.15  Med: 32.77 Max: 107.17
Current: 64.86
7.15
107.17
Forward P/E 24.75
BRKR's Forward P/E is ranked lower than
66% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. BRKR: 24.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 65.80
BRKR's PE(NRI) is ranked lower than
81% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. BRKR: 65.80 )
Ranked among companies with meaningful PE(NRI) only.
BRKR' s 10-Year PE(NRI) Range
Min: 7.21  Med: 32.66 Max: 98.6
Current: 65.8
7.21
98.6
P/B 4.99
BRKR's P/B is ranked lower than
64% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. BRKR: 4.99 )
Ranked among companies with meaningful P/B only.
BRKR' s 10-Year P/B Range
Min: 1.32  Med: 4.05 Max: 8.89
Current: 4.99
1.32
8.89
P/S 2.05
BRKR's P/S is ranked higher than
65% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. BRKR: 2.05 )
Ranked among companies with meaningful P/S only.
BRKR' s 10-Year P/S Range
Min: 0.5  Med: 1.71 Max: 2.55
Current: 2.05
0.5
2.55
PFCF 38.20
BRKR's PFCF is ranked lower than
60% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. BRKR: 38.20 )
Ranked among companies with meaningful PFCF only.
BRKR' s 10-Year PFCF Range
Min: 9.23  Med: 25.84 Max: 159.85
Current: 38.2
9.23
159.85
POCF 28.79
BRKR's POCF is ranked lower than
64% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. BRKR: 28.79 )
Ranked among companies with meaningful POCF only.
BRKR' s 10-Year POCF Range
Min: 5.78  Med: 19.98 Max: 478
Current: 28.79
5.78
478
EV-to-EBIT 31.31
BRKR's EV-to-EBIT is ranked lower than
71% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. BRKR: 31.31 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s 10-Year EV-to-EBIT Range
Min: -101.5  Med: 20.00 Max: 82
Current: 31.31
-101.5
82
PEG 131.60
BRKR's PEG is ranked lower than
97% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. BRKR: 131.60 )
Ranked among companies with meaningful PEG only.
BRKR' s 10-Year PEG Range
Min: 0.01  Med: 1.37 Max: 57.15
Current: 131.6
0.01
57.15
Shiller P/E 41.06
BRKR's Shiller P/E is ranked lower than
66% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. BRKR: 41.06 )
Ranked among companies with meaningful Shiller P/E only.
BRKR' s 10-Year Shiller P/E Range
Min: 20.11  Med: 37.08 Max: 509
Current: 41.06
20.11
509
Current Ratio 2.41
BRKR's Current Ratio is ranked lower than
53% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BRKR: 2.41 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s 10-Year Current Ratio Range
Min: 1.26  Med: 2.12 Max: 4.99
Current: 2.41
1.26
4.99
Quick Ratio 1.54
BRKR's Quick Ratio is ranked lower than
69% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. BRKR: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s 10-Year Quick Ratio Range
Min: 0.43  Med: 1.15 Max: 3.95
Current: 1.54
0.43
3.95
Days Inventory 201.83
BRKR's Days Inventory is ranked lower than
91% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. BRKR: 201.83 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s 10-Year Days Inventory Range
Min: 160.3  Med: 216.33 Max: 313.08
Current: 201.83
160.3
313.08
Days Sales Outstanding 47.78
BRKR's Days Sales Outstanding is ranked higher than
72% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. BRKR: 47.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s 10-Year Days Sales Outstanding Range
Min: 33.74  Med: 61.77 Max: 79.37
Current: 47.78
33.74
79.37

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.32
BRKR's Price/Net Current Asset Value is ranked lower than
73% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. BRKR: 14.32 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BRKR' s 10-Year Price/Net Current Asset Value Range
Min: 2.43  Med: 12.30 Max: 103.75
Current: 14.32
2.43
103.75
Price/Tangible Book 6.92
BRKR's Price/Tangible Book is ranked lower than
66% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. BRKR: 6.92 )
Ranked among companies with meaningful Price/Tangible Book only.
BRKR' s 10-Year Price/Tangible Book Range
Min: 1.35  Med: 5.40 Max: 20.45
Current: 6.92
1.35
20.45
Price/Projected FCF 2.38
BRKR's Price/Projected FCF is ranked lower than
58% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. BRKR: 2.38 )
Ranked among companies with meaningful Price/Projected FCF only.
BRKR' s 10-Year Price/Projected FCF Range
Min: 0.9  Med: 2.05 Max: 11.13
Current: 2.38
0.9
11.13
Price/Median PS Value 1.20
BRKR's Price/Median PS Value is ranked lower than
58% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. BRKR: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
BRKR' s 10-Year Price/Median PS Value Range
Min: 0.35  Med: 1.05 Max: 17.27
Current: 1.2
0.35
17.27
Price/Graham Number 4.40
BRKR's Price/Graham Number is ranked lower than
74% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. BRKR: 4.40 )
Ranked among companies with meaningful Price/Graham Number only.
BRKR' s 10-Year Price/Graham Number Range
Min: 1.07  Med: 3.11 Max: 17.07
Current: 4.4
1.07
17.07
Earnings Yield (Greenblatt) (%) 3.23
BRKR's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. BRKR: 3.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BRKR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.2  Med: 4.90 Max: 17.9
Current: 3.23
1.2
17.9
Forward Rate of Return (Yacktman) (%) -0.08
BRKR's Forward Rate of Return (Yacktman) (%) is ranked lower than
77% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.12 vs. BRKR: -0.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BRKR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -5.6  Med: 8.70 Max: 1478.7
Current: -0.08
-5.6
1478.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BKD.Germany,
Bruker Corp is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. Company manufacture and distribute a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also design, manufacture and market high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in advanced magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Company have broad an
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
Insiders New Buys: Bruker Corp Jun 22 2015 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
comment on BRKR Mar 23 2013 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 18 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 15 2010 

More From Other Websites
PerkinElmer Beats Q2 Earnings and Revenues; Guides Up - Analyst Blog Jul 31 2015
Newport (NEWP) Falls: Stock Goes Down 10.5% - Tale of the Tape Jul 21 2015
Bruker Announces Date and Time of Second Quarter 2015 Earnings Release and Webcast Jul 15 2015
Bruker Announces Date and Time of Second Quarter 2015 Earnings Release and Webcast Jul 15 2015
New Strong Buy Stocks for July 10th - Tale of the Tape Jul 10 2015
Bruker on Track with Maldi Product Line, NMR Holds Scope - Analyst Blog Jul 09 2015
Bruker Introduces Second-Generation Inspire Nanochemical Imaging Solution Jun 30 2015
Bruker CEO's $20M Stock Buy Jun 22 2015
Bruker (BRKR) Poised on Portfolio Strength across Segments - Analyst Blog Jun 15 2015
Edited Transcript of BRKR earnings conference call or presentation 6-May-15 8:45pm GMT Jun 11 2015
Bruker's Tissuetyper on rapifleX Expands MALDI Product Line - Analyst Blog Jun 04 2015
Bruker Introduces Comprehensive Mycobacteria Library 3.0 for High-Performance MALDI Biotyper... Jun 01 2015
Bruker Introduces MALDI Tissuetyper™ Solution with New High Speed rapifleX™ MALDI-TOF MS System... Jun 01 2015
Bruker Introduces Comprehensive Mycobacteria Library 3.0 for High-Performance MALDI Biotyper... Jun 01 2015
Bruker Announces MALDI PharmaPulse™, a Breakthrough High-Throughput Screening (HTS) Solution for... Jun 01 2015
Bruker Introduces Contour Elite 3D Optical Microscopes May 27 2015
Bruker (BRKR) Stock Falls After CFO's Resignation May 21 2015
Bruker Corp. downgraded by Mizuho May 21 2015
Williams-Sonoma, Salesforce.com, Deckers Outdoor Lead Wednesday's After-Hours Movers May 20 2015
Bruker Announces Resignation of Chief Financial Officer and Appointment of Interim Chief Financial... May 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK